KALA BIO (KALA) Projected to Post Earnings on Thursday

KALA BIO (NASDAQ:KALA) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect KALA BIO to post earnings of ($2.47) per share for the quarter.

KALA BIO Trading Down 0.9 %

NASDAQ:KALA opened at $6.86 on Tuesday. The company has a market capitalization of $41.78 million, a PE ratio of -0.55 and a beta of -2.19. KALA BIO has a 52-week low of $4.21 and a 52-week high of $11.20. The stock has a fifty day simple moving average of $7.74 and a 200-day simple moving average of $6.80. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a report on Thursday, February 13th.

Insider Transactions at KALA BIO

In other KALA BIO news, CEO Mark T. Iwicki sold 5,779 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. This represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bros. Advisors Lp Baker acquired 310,559 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was purchased at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the transaction, the insider now owns 1,083,398 shares of the company’s stock, valued at approximately $6,977,083.12. The trade was a 40.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 9,506 shares of company stock valued at $72,531 over the last three months. 8.32% of the stock is currently owned by insiders.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.